Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment

Maurizia Dalla Palma, Giuseppe Lombardi, Martin E. Donach, Lucia Borgato, Fable Zustovich, Lara Furini, Maria O. Nicoletto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives: This retrospective analysis aims at describing the safety profile of treatment with pegylated liposomal doxorubicin (PLD) and oxaliplatin in recurrent ovarian cancer patients who experienced myelotoxicity (principally neutropenia) during first line chemotherapy with carboplatin and paclitaxel. Methods: We reviewed the medical records of patients with relapsed ovarian cancer treated with PLD/Oxaliplatin at the Istituto Oncologico Veneto (IOV)/IRCCS, Padua University between 2002 and 2008. Results: A cohort of 16 patients who developed myelodepression and other toxicities of grade 3 to grade 4 during first line chemotherapy with carboplatin/paclitaxel, were selected for this retrospective study. Patients had developed predominantly grade 3 to grade 4 neutropenia and grade 1 to grade 3 thrombocytopenia as major toxicities during primary chemotherapy with carboplatin and paclitaxel. Following relapse or disease progression, PLD/oxaliplatin chemotherapy was administered at 30 to 35 and 70 mg/m, respectively, over 2 day, every 4 weeks. Conclusions: Complete regression and stabilization of bone marrow suppression and no allergic reactions were seen with PLD/oxaliplatin treatment. The estimated median overall survival was 51.2 months. PLD/oxaliplatin chemotherapy did not show hematological toxicity and was feasible and active in this group of pretreated frail patients.

Original languageEnglish
Pages (from-to)305-308
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume34
Issue number3
DOIs
Publication statusPublished - Jun 2011

Fingerprint

oxaliplatin
Carboplatin
Paclitaxel
Ovarian Neoplasms
Drug Therapy
Neutropenia
Therapeutics
Medical Records
Disease Progression
Hypersensitivity
Retrospective Studies
Bone Marrow
liposomal doxorubicin
Safety
Recurrence

Keywords

  • carboplatin
  • myelotoxicity
  • ovarian cancer
  • oxaliplatin
  • paclitaxel
  • pegylated liposomal doxorubicin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment. / Palma, Maurizia Dalla; Lombardi, Giuseppe; Donach, Martin E.; Borgato, Lucia; Zustovich, Fable; Furini, Lara; Nicoletto, Maria O.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 34, No. 3, 06.2011, p. 305-308.

Research output: Contribution to journalArticle

@article{6e5555c7b75f4d9c92f1829c47a6e8cd,
title = "Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment",
abstract = "Objectives: This retrospective analysis aims at describing the safety profile of treatment with pegylated liposomal doxorubicin (PLD) and oxaliplatin in recurrent ovarian cancer patients who experienced myelotoxicity (principally neutropenia) during first line chemotherapy with carboplatin and paclitaxel. Methods: We reviewed the medical records of patients with relapsed ovarian cancer treated with PLD/Oxaliplatin at the Istituto Oncologico Veneto (IOV)/IRCCS, Padua University between 2002 and 2008. Results: A cohort of 16 patients who developed myelodepression and other toxicities of grade 3 to grade 4 during first line chemotherapy with carboplatin/paclitaxel, were selected for this retrospective study. Patients had developed predominantly grade 3 to grade 4 neutropenia and grade 1 to grade 3 thrombocytopenia as major toxicities during primary chemotherapy with carboplatin and paclitaxel. Following relapse or disease progression, PLD/oxaliplatin chemotherapy was administered at 30 to 35 and 70 mg/m, respectively, over 2 day, every 4 weeks. Conclusions: Complete regression and stabilization of bone marrow suppression and no allergic reactions were seen with PLD/oxaliplatin treatment. The estimated median overall survival was 51.2 months. PLD/oxaliplatin chemotherapy did not show hematological toxicity and was feasible and active in this group of pretreated frail patients.",
keywords = "carboplatin, myelotoxicity, ovarian cancer, oxaliplatin, paclitaxel, pegylated liposomal doxorubicin",
author = "Palma, {Maurizia Dalla} and Giuseppe Lombardi and Donach, {Martin E.} and Lucia Borgato and Fable Zustovich and Lara Furini and Nicoletto, {Maria O.}",
year = "2011",
month = "6",
doi = "10.1097/COC.0b013e3181e1cb22",
language = "English",
volume = "34",
pages = "305--308",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment

AU - Palma, Maurizia Dalla

AU - Lombardi, Giuseppe

AU - Donach, Martin E.

AU - Borgato, Lucia

AU - Zustovich, Fable

AU - Furini, Lara

AU - Nicoletto, Maria O.

PY - 2011/6

Y1 - 2011/6

N2 - Objectives: This retrospective analysis aims at describing the safety profile of treatment with pegylated liposomal doxorubicin (PLD) and oxaliplatin in recurrent ovarian cancer patients who experienced myelotoxicity (principally neutropenia) during first line chemotherapy with carboplatin and paclitaxel. Methods: We reviewed the medical records of patients with relapsed ovarian cancer treated with PLD/Oxaliplatin at the Istituto Oncologico Veneto (IOV)/IRCCS, Padua University between 2002 and 2008. Results: A cohort of 16 patients who developed myelodepression and other toxicities of grade 3 to grade 4 during first line chemotherapy with carboplatin/paclitaxel, were selected for this retrospective study. Patients had developed predominantly grade 3 to grade 4 neutropenia and grade 1 to grade 3 thrombocytopenia as major toxicities during primary chemotherapy with carboplatin and paclitaxel. Following relapse or disease progression, PLD/oxaliplatin chemotherapy was administered at 30 to 35 and 70 mg/m, respectively, over 2 day, every 4 weeks. Conclusions: Complete regression and stabilization of bone marrow suppression and no allergic reactions were seen with PLD/oxaliplatin treatment. The estimated median overall survival was 51.2 months. PLD/oxaliplatin chemotherapy did not show hematological toxicity and was feasible and active in this group of pretreated frail patients.

AB - Objectives: This retrospective analysis aims at describing the safety profile of treatment with pegylated liposomal doxorubicin (PLD) and oxaliplatin in recurrent ovarian cancer patients who experienced myelotoxicity (principally neutropenia) during first line chemotherapy with carboplatin and paclitaxel. Methods: We reviewed the medical records of patients with relapsed ovarian cancer treated with PLD/Oxaliplatin at the Istituto Oncologico Veneto (IOV)/IRCCS, Padua University between 2002 and 2008. Results: A cohort of 16 patients who developed myelodepression and other toxicities of grade 3 to grade 4 during first line chemotherapy with carboplatin/paclitaxel, were selected for this retrospective study. Patients had developed predominantly grade 3 to grade 4 neutropenia and grade 1 to grade 3 thrombocytopenia as major toxicities during primary chemotherapy with carboplatin and paclitaxel. Following relapse or disease progression, PLD/oxaliplatin chemotherapy was administered at 30 to 35 and 70 mg/m, respectively, over 2 day, every 4 weeks. Conclusions: Complete regression and stabilization of bone marrow suppression and no allergic reactions were seen with PLD/oxaliplatin treatment. The estimated median overall survival was 51.2 months. PLD/oxaliplatin chemotherapy did not show hematological toxicity and was feasible and active in this group of pretreated frail patients.

KW - carboplatin

KW - myelotoxicity

KW - ovarian cancer

KW - oxaliplatin

KW - paclitaxel

KW - pegylated liposomal doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=79958292487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958292487&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181e1cb22

DO - 10.1097/COC.0b013e3181e1cb22

M3 - Article

C2 - 20622643

AN - SCOPUS:79958292487

VL - 34

SP - 305

EP - 308

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -